Bicara Therapeutics BCAX Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Bicara Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The official record: Bicara Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →
Ask your AI about Bicara Therapeutics's business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Bicara Therapeutics's business segments — net loss?
- Bicara Therapeutics (BCAX) reported business segments — net loss of -$56.21M in Q1 2026.
- How has Bicara Therapeutics's business segments — net loss changed year-over-year?
- Bicara Therapeutics's business segments — net loss decreased by 52.6% year-over-year, from -$36.85M to -$56.21M.
- What is the long-term trend for Bicara Therapeutics's business segments — net loss?
- Over 2 years (2023 to 2025), Bicara Therapeutics's business segments — net loss has grown at a 62.9% compound annual growth rate (CAGR), from -$51.99M to -$137.95M.
- What does business segments — net loss mean?
- This metric represents the final bottom-line financial result after all operating expenses, taxes, and other non-operating items have been accounted for. For early-stage biopharmaceutical companies, this typically reflects the heavy investment in clinical trials and drug development relative to revenue generation.